SG/PUT/BRISTOL-MYERS SQUIBB/60/0.1/21.06.24 | Delayed Deutsche Boerse AG 18:18:23 03/06/2024 BST | ||
| 1.67 EUR | -5.11% |
|
| 1 month | +18.92% | ||
| 3 months | +95.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 1.67 | -5.11% |
| 31/05/24 | 1.76 | -2.76% |
| 30/05/24 | 1.81 | 0.00% |
| 29/05/24 | 1.81 | +1.12% |
| 28/05/24 | 1.79 | +5.92% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 06:18 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ6K9U |
| ISIN | DE000SQ6K9U3 |
| Date issued | 20/12/2022 |
| Strike | 60 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 10 : 1 |
| Emission price | 0.34 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.83 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.01 € |
| Spread % | 0.60% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Warrants
- Warrant
